CVS Health (CVS) Form 4 CVS HEALTH / Troyen A Brennan ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Brennan Troyen A

(Last) (First) (Middle)

ONE CVS DRIVE

(Street)

WOONSOCKET RI 02895

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CVS HEALTH Corp [ CVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
EVP and Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2022

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/03/2022		M		47,937	A	$102.26	186,183.059	D
Common Stock	02/03/2022		S(1)		47,937	D	$110	138,246.059	D
Common Stock (restricted)								4,805	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$102.26	02/03/2022		M			47,937	04/01/2016(2)	04/01/2022	Common Stock	47,937	$0	0	D
Stock Option	$104.82							04/01/2017(3)	04/01/2023	Common Stock	53,772		53,772	D
Stock Option	$78.05							04/03/2018(4)	04/03/2024	Common Stock	75,134		75,134	D
Stock Option	$62.21							04/01/2019(5)	04/01/2025	Common Stock	21,894		21,894	D
Stock Option	$54.19							04/01/2020(6)	04/01/2029	Common Stock	80,803		80,803	D
Stock Option	$58.34(7)							04/01/2021(8)	04/01/2030	Common Stock	84,478		84,478	D
Stock Option	$74.3							04/01/2022(9)	04/01/2031	Common Stock	99,344		99,344	D

Explanation of Responses:

1. All sales were effected pursuant to a Rule 10b5-1 plan.

2. Option became exercisable in four equal annual installments, commencing 4/1/2016.

3. Option became exercisable in four equal annual installments, commencing 4/1/2017.

4. Option became exercisable in four equal annual installments, commencing 4/3/2018.

5. Option became exercisable in four equal annual installments, commencing 4/1/2019.

6. Option became exercisable in four equal annual installments, commencing 4/1/2020.

7. The number of shares subject to the option were calculated using a 30-day average price.

8. Options became exercisable in four equal annual installments, commencing 4/1/2021.

9. Option becomes exercisable in four equal annual installments, commencing 4/1/2022.

	/s/ Troyen Brennan	02/04/2022
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.